Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis - 29/08/11
Abstract |
Background: Effective, rapid-acting, safe therapies are needed for the long-term treatment of psoriasis. Objective: We sought to evaluate infliximab monotherapy in maintaining clinical benefit in psoriasis. Methods: A total of 33 patients received 3 doses of 5 or 10 mg/kg of infliximab or placebo at weeks 0, 2, and 6 (double-blind phase). During the open-label phase (weeks 10-26), responding patients were evaluated for relapse (loss of at least half of the improvement in the Psoriasis Area Severity Index score at week 10) and retreated with open-label infliximab (5 or 10 mg/kg) as needed. Placebo nonresponders were treated with an induction regimen of infliximab (5 or 10 mg/kg) and followed up through week 26. Results: In all, 29 patients received either 5 or 10 mg/kg of infliximab in the open-label extension. At week 26, psoriasis area severity index response was maintained in 40% and 73% of patients receiving 5 and 10 mg/kg of infliximab, respectively. Conclusion: Infliximab produced a rapid, effective, and sustainable (through week 26) effect in patients with moderate to severe psoriasis. (J Am Acad Dermatol 2003;48:829-35.)
Le texte complet de cet article est disponible en PDF.Plan
Supported in part by a Corporate Office of Science and Technology grant from the Johnson and Johnson Focused Giving Program, the David Ju Foundation, and Centocor Inc. |
|
Disclosure: Some authors are employees of (L. D. M, S. L., L. T. D., and D. G. B.) or a consultant to (A. B. G.) Centocor Inc, a member of the Johnson & Johnson family of companies. |
|
Reprint requests: Alice B. Gottlieb, MD, PhD, the Clinical Research Center, University of Medicine and Dentistry of New Jersey-The Robert Wood Johnson Medical School, 51 French St, New Brunswick, NJ 08901-0019. E-mail: gottliab@umdnj.edu. |
|
0190-9622/2003/$30.00 + 0 |
Vol 48 - N° 6
P. 829-835 - juin 2003 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?